177Lu-/68Ga-PSMA Theranostics in Recurrent Glioblastoma Multiforme

Kumar, Arunav; Ballal, Sanjana; Yadav, Madhav P.; Arunraj, Sreedharan Thankarajan; Haresh, K.P.; Gupta, Subhash; Damle, Nishikant; Garg, Ajay; Tripathi, Madhavi; Bal, Chandrasekhar

doi:10.1097/rlu.0000000000003142

Cited by 33 publications

(27 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bearing this in mind, we conclude that salivary gland cancer, glioblastoma, thyroid cancer (differentiated and medullary), hepatocellular carcinoma, and renal cell cancer (clear cell) are the most relevant tumors to further explore the potential of PSMA-RLT. In line with this, the first case reports on PSMA-RLT in patients other than prostate cancer included salivary gland cancer, glioblastoma, thyroid cancer, and hepatocellular carcinoma [30,34,53,55,76,77,102]. These nine heavily pretreated end-stage patients received 1-2 cycles of 5.9-8.4 GBq [ 177 Lu]Lu-PSMA per cycle in compassionate use programs (Table 2).…”

Section: Discussionmentioning

confidence: 87%

“…One thyroid cancer patient showed a partial response that lasted 7 months [77]. In a glioblastoma patient, tumor volume decreased upon PSMA-RLT [55]. Importantly, the treatment was generally well tolerated, with no or low-grade adverse events.…”

Section: Discussionmentioning

confidence: 98%

“…It has been speculated that PSMA expression solely on the neovasculature could result in a shortened tracer washout [53,94], meaning that PSMA-RLT is not retained in the tumor for a longer time, resulting in a lower radiation dose to the tumor and less effective treatment. Yet, a case report on a glioblastoma patient treated with [ 177 Lu]Lu-PSMA showed good tumor tracer retention on post-therapy imaging, resulting in a substantial tumor absorbed dose [53], and in another glioblastoma patient, [ 177 Lu]Lu-PSMA treatment resulted in a decrease in tumor volume [55]. This suggests that a sufficient radiation dose might still be reached while PSMA expression is limited to the tumor vasculature.…”

Section: Discussionmentioning

confidence: 99%

“…Abbreviations: NA not applicable, NR not reported, h hours, d days, RLT radioligand therapy, PFS progression-free survival, PR partial response *Efficacy: this included any of the following: objective or subjective response, progression-free survival, overall survival, quality of life with these conclusions[49][50][51][53][54][55].…”

mentioning

confidence: 99%

See 3 more Smart Citations

PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports

Uijen¹,

Derks

Merkx³

et al. 2021

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

In the past decade, a growing body of literature has reported promising results for prostate-specific membrane antigen (PSMA)-targeted radionuclide imaging and therapy in prostate cancer. First clinical studies evaluating the efficacy of [177Lu]Lu-PSMA radioligand therapy (PSMA-RLT) demonstrated favorable results in prostate cancer patients. [177Lu]Lu-PSMA is generally well tolerated due to its limited side effects. While PSMA is highly overexpressed in prostate cancer cells, varying degrees of PSMA expression have been reported in other malignancies as well, particularly in the tumor-associated neovasculature. Hence, it is anticipated that PSMA-RLT could be explored for other solid cancers. Here, we describe the current knowledge of PSMA expression in other solid cancers and define a perspective towards broader clinical implementation of PSMA-RLT. This review focuses specifically on salivary gland cancer, glioblastoma, thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, lung cancer, and breast cancer. An overview of the (pre)clinical data on PSMA immunohistochemistry and PSMA PET/CT imaging is provided and summarized. Furthermore, the first clinical reports of non-prostate cancer patients treated with PSMA-RLT are described.

show abstract

Section: Discussionmentioning

confidence: 87%

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports

Uijen¹,

Derks

Merkx³

et al. 2021

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…Only one case is reported in the literature regarding PRRT with PSMA-targeted radiopharmaceuticals in a patient with glioblastoma multiforme [30].…”

Section: Gliomasmentioning

confidence: 99%

Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview

et al. 2021

View full text Add to dashboard Cite

Primary brain tumors (PBTs) are some of the most difficult types of cancer to treat, and despite advancements in surgery, chemotherapy and radiotherapy, new strategies for the treatment of PBTs are needed, especially for those with poor prognosis such as inoperable/difficult-to-reach lesions or relapsing disease. In regard to the last point, malignant primary brain tumors remain some of the most lethal types of cancer. Nuclear medicine may provide exciting new weapons and significant contributions in the treatment of PBTs. In this review, we performed literature research in order to highlight the possible role of peptide receptor radionuclide therapy (PRRT) in the treatment of PBTs with radiolabeled molecules that bind with high-affinity transmembrane receptors such as somatostatin receptors (SSTRs), neurokinin type-1 receptor and prostate-specific membrane antigen (PSMA). These receptors are overexpressed in some cancer types such as gliomas, meningiomas, pituitary tumors and medulloblastomas. A comprehensive overview of possible applications in this field will be shown, providing knowledge about benefits, feasibility, developments and limitations of PRRT in this type of tumor, also revealing new advantages in the management of the disease.

show abstract